English Spanish
Daavlin

Phototherapy vs. Biological Drug Therapy

 

Compare the Safety of Ultraviolet Phototherapy vs. Biological Drugs Used for the Treatment of Skin Disease

While biological drug therapies have become popular in the last few years, it is important to evaluate the safety of these medications. Every one of the following drugs has had numerous adverse effects and deaths where the drug was listed as the primary suspected cause.

In contrast, Daavlin’s phototherapy is an extremely safe and effective method of treatment. Even Oxsoralen, a drug used in conjunction with ultraviolet light to create PUVA, has an exemplary safety record.

We invite you to view the statistics of our competitors. Click the links to read FDA statements and other related information.

Adverse Effects:

Primary
Suspect
2000-2001 2002-2003 2004-2005 2006-2007 Total:
Enbrel 10,721 2,633 4,254 21,140 38,748
Humira 23 4,112 9,851 6,573 20,559
Remicade 3,357 5,184 5,232 4,537 18,310
Methotrexate 633 888 779 284 2,584
Raptiva* 4 11 818 471 1,304*
Elidel 3 259 302 64 628
Protopic 70 50 103 79 302
Oxsoralen (PUVA) 3 0 0 0 3

Deaths:

Primary
Suspect
2000-2001 2002-2003 2004-2005 2006-2007 Total:
Enbrel 510 344 227 311 1,392
Humira 6 130 520 347 1,003
Remicade 396 640 505 372 1,913
Methotrexate 109 122 120 36 387
Raptiva* 1 1 15 28 45*
Elidel 0 3 5 1 9
Protopic 0 5 0 0 5
Oxsoralen (PUVA) 0 0 0 0 0

*Although appearing to be the most innocuous of the biologic drugs in the comparison above; Raptiva was removed from the U.S. market on April 8, 2009 due to the risk of PML, a fatal brain infection.

Data compiled using MedWatch statistics available at FDA.gov

Enbrel is a registered trademark of Amgen, Inc. / Wyeth Pharmaceuticals.
Humira is a registered trademark of Abbott Laboratories.
Remicade is a registered trademark of Centocor, Inc.
Raptiva is a registered trademark of Genentech.
Elidel is a registered trademark of Novartis.
Protopic is a registered trademark of Astellas Pharma.

Share this page: